CD33 and myeloid neoplasm: TriKE (161533) comprises two single-chain variable fragments (scFvs), one that binds to CD16 on NK cells and another that binds to CD33 on myeloid malignancies, plus an IL-15 linker bridging the CD16 and CD33 scFvs for sustained cell activation [112].